News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,035 Results
Type
Article (8060)
Company Profile (140)
Press Release (475930)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166771)
Career Advice (304)
Deals (25742)
Drug Delivery (7)
Drug Development (52905)
Employer Resources (14)
FDA (9760)
Job Trends (8577)
News (238228)
Policy (17898)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (484)
Accelerated approval (23)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33154)
ALS (103)
Alzheimer's disease (972)
Antibody-drug conjugate (ADC) (261)
Approvals (10359)
Artificial intelligence (317)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (107)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (504)
Cancer (3613)
Cardiovascular disease (216)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (473)
Cervical cancer (34)
Clinical research (47831)
Collaboration (1227)
Commercialization (2)
Compensation (1423)
Complete response letters (34)
COVID-19 (759)
CRISPR (63)
C-suite (728)
Cystic fibrosis (84)
Data (5578)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (339)
Diagnostics (4174)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73448)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87565)
Executive appointments (695)
FDA (12346)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (901)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (291)
Government (940)
Grass and pollen (2)
Guidances (280)
Healthcare (9311)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (947)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (249)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (61)
Legal (5195)
Licensing (5)
Liver cancer (44)
Longevity (15)
Lung cancer (501)
Lymphoma (248)
Machine learning (27)
Management (3)
Manufacturing (523)
Marketing (7)
MASH (117)
Medical device (8650)
Medtech (8786)
Mergers & acquisitions (14373)
Metabolic disorders (699)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (218)
Neuropsychiatric disorders (38)
Neuroscience (1810)
NextGen: Class of 2026 (3164)
Non-profit (841)
Obesity (221)
Opinion (11)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (193)
Parkinson's disease (200)
Partnered (11)
Patents (464)
Patient recruitment (496)
Peanut (31)
People (41189)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15464)
Phase 2 (21367)
Phase 3 (14391)
Pipeline (6989)
Policy (18)
Postmarket research (1570)
Preclinical (6533)
Press Release (34)
Prostate cancer (188)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (567)
Real estate (3020)
Recruiting (6)
Regulatory (14763)
Reports (17)
Research institute (579)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (151)
Series B (119)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (87)
Sponsored (5)
Startups (2024)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (76)
Date
Last 7 days (508)
Last 30 days (1420)
Last 365 days (19024)
2026 (11619)
2025 (19251)
2024 (22988)
2023 (26540)
2022 (34593)
2021 (37184)
2020 (33493)
2019 (23260)
2018 (17471)
2017 (18771)
2016 (17918)
2015 (24269)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17874)
Australia (2096)
California (11762)
Canada (3092)
China (510)
Colorado (475)
Connecticut (400)
Delaware (205)
Europe (24614)
Florida (1753)
Georgia (369)
Hawaii (3)
Idaho (46)
Illinois (692)
India (45)
Indiana (314)
Iowa (14)
Japan (395)
Kansas (99)
Kentucky (30)
Louisiana (26)
Maine (25)
Maryland (1179)
Massachusetts (7757)
Michigan (304)
Minnesota (555)
Mississippi (4)
Missouri (79)
Montana (20)
Nebraska (11)
Nevada (113)
New Hampshire (60)
New Jersey (2586)
New Mexico (12)
New York (2784)
North Carolina (1254)
North Dakota (4)
Northern California (5873)
Ohio (273)
Oklahoma (14)
Oregon (18)
Pennsylvania (2231)
Puerto Rico (20)
Rhode Island (30)
South America (407)
South Carolina (76)
South Dakota (1)
Southern California (4885)
Tennessee (116)
Texas (1898)
United States (38273)
Utah (356)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (910)
West Virginia (1)
Wisconsin (73)
484,035 Results for "otonomy inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Otonomy Announces Change in Stock Exchange Listing
Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022.
December 22, 2022
·
1 min read
Business
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Otonomy, Inc. reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities.
November 10, 2022
·
7 min read
Deals
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.
March 29, 2023
·
4 min read
Biotech Beach
Otonomy Provides Corporate Update - December 19, 2022
Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.
December 19, 2022
·
6 min read
Biotech Beach
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy, Inc. announced that management will participate in the following virtual investor conference events.
February 28, 2022
·
1 min read
Biotech Beach
Otonomy Reports Corporate and Product Pipeline Update
Otonomy, Inc. today provided an update on its product pipeline and financial guidance.
January 6, 2022
·
11 min read
Biotech Beach
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
Otonomy, Inc. today announced multiple presentations at the upcoming Neuroscience 2021 meeting
October 27, 2021
·
3 min read
Biotech Beach
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced its participation in the H.C. Wainwright Global Investment Conference.
May 18, 2022
·
1 min read
Business
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Otonomy, Inc.Otonomy, Inc.Otonomy, Inc.Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the quarter ended June 30, 2021 and provided an update on its product pipeline and corporate activities.
August 4, 2021
·
14 min read
Business
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2022 and provided an update on its product pipeline and corporate activities.
July 25, 2022
·
13 min read
1 of 48,404
Next
